Jane A. Leopold

Dr. Jane A. Leopold

Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in Trends in Cardiovascular Medicine
Verified
Journal Article
Closed access
Jane A. LeopoldJane A. Leopold
Jane A. Leopold

4 February 2007 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Jane A. LeopoldJane A. Leopold
Jane A. Leopold
ADAamir Dam
Aamir Dam
BMBradley A Maron
Bradley A Maron
ASAnne W Scribner
Anne W Scribner
RLRonglih Liao
Ronglih Liao
JLJoseph Loscalzo
Joseph Loscalzo

1 August 2012 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
Jane A. LeopoldJane A. Leopold
Jane A. Leopold
Acquired aortic valve disease and valvular calcification is highly prevalent in adult populations worldwide and is associated with significant cardiovascular morbidity and mortality. At present, there are no medical therapies that will prevent or regress aortic valve calcification or stenosis and surgical or transcatheter aortic valve replacement remain the only effective therapies for treating this disease. In the setting of valve injury as a result of exposure to biochemical mediators or hemodynamic forces, normal homeostatic processes are disrupted resulting in extracellular matrix degradation, aberrant matrix deposition and fibrosis, inflammatory cell infiltration, lipid accumulation, and neoangiogenesis of the valve tissue and, ultimately, calcification of the valve. Calcification of the aortic valve is now understood to be an active process that involves the coordinated actions of resident valve endothelial and interstitial cells, circulating inflammatory and immune cells, and bone marrow-derived cells. These cells may undergo a phenotype transition to become osteoblast-like cells and elaborate bone matrix, endothelial-to-mesenchymal transition, and form matrix vesicles that serve as a nidus for microcalcifications. Each of these mechanisms has been shown to contribute to aortic valve calcification suggesting that strategies that target these cellular events may lead to novel therapeutic interventions to halt the progression or reverse aortic valve calcification.

Verified
Journal Article
Open access
PDF file
Jane A. LeopoldJane A. Leopold
Jane A. Leopold
BMBradley A. Maron
Bradley A. Maron
Pulmonary arterial hypertension (PAH) is a devastating disease that is precipitated by hypertrophic pulmonary vascular remodeling of distal arterioles to increase pulmonary artery pressure and pulmonary vascular resistance in the absence of left heart, lung parenchymal, or thromboembolic disease. Despite available medical therapy, pulmonary artery remodeling and its attendant hemodynamic consequences result in right ventricular dysfunction, failure, and early death. To limit morbidity and mortality, attention has focused on identifying the cellular and molecular mechanisms underlying aberrant pulmonary artery remodeling to identify pathways for intervention. While there is a well-recognized heritable genetic component to PAH, there is also evidence of other genetic perturbations, including pulmonary vascular cell DNA damage, activation of the DNA damage response, and variations in microRNA expression. These findings likely contribute, in part, to dysregulation of proliferation and apoptosis signaling pathways akin to what is observed in cancer; changes in cellular metabolism, metabolic flux, and mitochondrial function; and endothelial-to-mesenchymal transition as key signaling pathways that promote pulmonary vascular remodeling. This review will highlight recent advances in the field with an emphasis on the aforementioned molecular mechanisms as contributors to the pulmonary vascular disease pathophenotype.

29 November 2012 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JBJoshua A. F. Balderman
Joshua A. F. Balderman
HLHae‐Young Lee
Hae‐Young Lee
CMChristopher E. Mahoney
Christopher E. Mahoney
DHDiane Handy
Diane Handy
KWKevin White
Kevin White
Jane A. LeopoldJane A. Leopold
Jane A. Leopold
Background: Vascular calcification resembles bone formation and involves vascular smooth muscle cell ( SMC ) transition to an osteoblast‐like phenotype to express Runx2 , a master osteoblast transcription factor. One possible mechanism by which Runx2 protein expression is induced is downregulation of inhibitory micro RNA s (mi R ). Methods and Results: Human coronary artery SMCs ( CASMCs ) treated with bone morphogenetic protein‐2 ( BMP ‐2; 100 ng/mL) demonstrated a 1.7‐fold ( P <0.02) increase in Runx2 protein expression at 24 hours. A mi R microarray and target prediction database analysis independently identified mi R ‐30b and mi R ‐30c (mi R ‐30b‐c) as mi R s that regulate Runx2 expression. Real‐time–polymerase chain reaction confirmed that BMP ‐2 decreased mi R ‐30b and mi R ‐30c expression. A luciferase reporter assay verified that both mi R ‐30b and mi R ‐30c bind to the 3′‐untranslated region of R unx2 m RNA to regulate its expression. CASMCs transfected with antagomirs to downregulate mi R ‐30b‐c demonstrated significantly increased R unx2, intracellular calcium deposition, and mineralization. Conversely, forced expression of mi R ‐30b‐c by transfection with pre–mi R ‐30b‐c prevented the increase in Runx2 expression and mineralization of SMCs . Calcified human coronary arteries demonstrated higher levels of BMP ‐2 and lower levels of mi R ‐30b than did noncalcified donor coronary arteries. Conclusions: BMP ‐2 downregulates mi R ‐30b and mi R ‐30c to increase Runx2 expression in CASMCs and promote mineralization. Strategies that modulate expression of mi R ‐30b and mi R ‐30c may influence vascular calcification.

1 March 2015 in Coronary Artery Disease
Verified
Journal Article
Closed access
Jane A. LeopoldJane A. Leopold
Jane A. Leopold
Oxidant stress in the cardiovascular system may occur when antioxidant capacity is insufficient to reduce reactive oxygen species and other free radicals. Oxidant stress has been linked to the pathogenesis of atherosclerosis and incident coronary artery disease. As a result of this connection, early observational studies focused on dietary antioxidants, such as β-carotene, α-tocopherol, and ascorbic acid, and demonstrated an inverse relationship between intake of these antioxidants and major adverse cardiovascular events. These findings supported a number of randomized trials on the use of selected antioxidants as primary or secondary prevention strategies to decrease cardiac risk; however, many of these studies reported disappointing results with little or no observed risk reduction in antioxidant-treated patients. Several plausible explanations for these findings have been suggested, including incorrect antioxidant choice or dose, synthetic versus dietary antioxidants as the intervention, and patient selection, all of which will be important to consider when designing future clinical trials. This review will focus on the contemporary evidence that is the basis for our current understanding of the role of antioxidants in cardiovascular disease prevention.